Role of the ATP7A Transporter in Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

May 1, 2023

Study Completion Date

January 1, 2024

Conditions
Gynecologic CancerOvarian CancerHigh Grade Serous CarcinomaChemotherapy Effect
Interventions
DRUG

Carboplatin

Patients will receive neoadjuvant chemotherapy according to ESGO guidelines

Trial Locations (2)

1000

Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center, Ljubljana

Unknown

Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana., Ljubljana

All Listed Sponsors
collaborator

University of Ljubljana, Faculty of Medicine, Institute of Pharmacology and Experimental Toxicology

UNKNOWN

lead

University Medical Centre Ljubljana

OTHER

NCT05490407 - Role of the ATP7A Transporter in Ovarian Cancer | Biotech Hunter | Biotech Hunter